Financial results reflect the economic challenges of 2012, but stock values point to optimism

Chemists meet demand for novel ingredients that repair, add shine, and protect color

Patient advocates and companies are encouraged by the recent introduction of new regulatory tools to speed the development of drugs for rare diseases but worry they may not go far enough for the smallest patient groups

Although companies ultimately bring treatments to market, it’s patient groups that are creating the awareness needed to start the drug discovery process

The current groundswell of interest in rare diseases can be traced to Genzyme, the first firm to show that drugs for small patient populations could be profitable

After years of neglect by pharma companies, rare disease treatment is coming into the limelight

Program set for ACS gathering in La Crosse, Wis.

State Department program brings ACS career development training to Malaysia and Indonesia

Science is becoming increasingly important in diplomatic efforts at the State Department

ACS Meeting News: Courses aim to engage students who don’t know the difference between a beaker and a Bunsen burner